Korean J Fam Med. 2020 Sep;41(5):339-345. doi: 10.4082/kjfm.19.0110. Epub 2020 May 25.

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study.

Korean journal of family medicine

Yong Ho Cho, Kyung Hyun Bae, Dong Ryul Lee, Jungun Lee

PMID: 32447881 PMCID: PMC7509122 DOI: 10.4082/kjfm.19.0110

Abstract

BACKGROUND: Intermittent dosing regimens for oral risedronate (once-monthly and once-weekly) were developed for patient convenience. While several studies have reported the anti-fracture efficacy of weekly dosing, few have assessed monthly dosing. The lower efficacy of monthly dosing has been previously suggested. The aim of this study was to compare the anti-fracture efficacy of monthly and weekly dosing.

METHODS: We obtained information from the Korea National Health Insurance Service database from 2012 to 2017 of Korean women of ≥50 years of age who used weekly or monthly risedronate. We compared the time of occurrence of the first osteoporotic fracture after the first prescription of risedronate. Using a Cox proportional model, we assessed incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for fractures at any site, and the hip, vertebral, and non-vertebral sites between both regimens. Propensity score weighting was used to balance the treatment groups.

RESULTS: The study populations were distributed according to dosing frequency (monthly, 27,329; weekly, 47,652). There was no significant difference in the incidence rate of new fractures in any site (IRR, 1.008; 95% CI,0.963- 1.055; P=0.737), hip (IRR, 0.999; 95% CI, 0.769-1.298; P=0.996), vertebral (IRR, 0.962; 95% CI, 0.890-1.040; P=0.330), or non-vertebral (1.022; 95% CI, 0.968-1.078; P=0.439) sites between monthly and weekly risedronate.

CONCLUSION: The anti-fracture efficacy at any site and the examined individual sites was similar for the monthly and weekly risedronate regimens. Large-scale randomized controlled trials are required for confirmation.

Keywords: Bisphosphonate; Fracture; Osteoporosis; Risedronic Acid

References

1. Curr Med Res Opin. 2007 Dec;23(12):3079-89 - PubMed
2. N Engl J Med. 2001 Feb 1;344(5):333-40 - PubMed
3. Osteoporos Int. 2019 Mar;30(3):659-666 - PubMed
4. Bone. 2006 May;38(5):617-27 - PubMed
5. Am J Med. 2009 Feb;122(2 Suppl):S3-13 - PubMed
6. Korean J Fam Med. 2019 May;40(3):135-142 - PubMed
7. JAMA. 1999 Oct 13;282(14):1344-52 - PubMed
8. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42 - PubMed
9. Calcif Tissue Int. 2002 Aug;71(2):103-11 - PubMed
10. Osteoporos Int. 2013 Jan;24(1):293-9 - PubMed
11. Arthritis Rheum. 2001 Jul;44(7):1496-503 - PubMed
12. Yonsei Med J. 2014 Jul;55(4):1049-57 - PubMed
13. Korean J Fam Med. 2018 Mar;39(2):74-84 - PubMed
14. Osteoporos Int. 2013 Jan;24(1):301-10 - PubMed
15. Korean J Fam Med. 2019 Mar;40(2):100-105 - PubMed
16. Calcif Tissue Int. 2013 Aug;93(2):137-46 - PubMed
17. JAMA. 2009 Feb 4;301(5):513-21 - PubMed
18. Clin Ther. 2009 Feb;31(2):272-85 - PubMed
19. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):139-47 - PubMed
20. Calcif Tissue Int. 2017 Dec;101(6):623-630 - PubMed
21. Bone. 2008 Jan;42(1):36-42 - PubMed
22. Osteoporos Int. 2015 Nov;26(11):2685-93 - PubMed
23. Osteoporos Int. 2008 Jul;19(7):1039-45 - PubMed
24. J Clin Endocrinol Metab. 2006 Jul;91(7):2631-7 - PubMed
25. Osteoporos Int. 2016 Oct;27(10):2935-44 - PubMed
26. J Korean Med Sci. 2015 Apr;30(4):483-8 - PubMed
27. J Bone Miner Metab. 2017 Jul;35(4):419-427 - PubMed
28. Osteoporos Int. 2014 Dec;25(12):2729-41 - PubMed

Publication Types

• Journal Article

Grant support

• Wonkwang University